+32.1%
GSK vs SARO
-22.5%
+54.6%
-19.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | SARO | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | +1.6% | -1.6% | -0.1% |
| 7D | -3.5% | -3.1% | -0.4% | -3.3% |
| 30D | -3.4% | -12.2% | +8.8% | -2.5% |
| 3M | -8.1% | -7.4% | -0.8% | -7.7% |
| 6M | -11.1% | -15.3% | +4.1% | -10.4% |
| YTD | +0.7% | -16.2% | +16.9% | +1.5% |
| 1Y | +20.1% | -12.1% | +32.2% | +20.6% |
| All | +32.1% | -22.5% | +54.6% | +27.7% |
Cumulative growth
Daily Returns
Daily percentage return beside SARO.
Daily Out/Under-Performance
Portfolio return minus SARO return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × SARO return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded SARO wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling